|
Report No. 108 - AAPM Task Group 108: PET and PET/CT Shielding Requirements (2006) Category: Reports The shielding of positron emission tomography (PET) and PET/CT (computed tomography) facili- ties presents special challenges. The 0.511 MeV annihilation photons associated with positron decay are much higher energy than other diagnostic radiations. As a result, barrier shielding may be required in floors and ceilings as well as adjacent walls. Since the patient becomes the radioactive source after the radiopharmaceutical has been administered, one has to consider the entire time that the subject remains in the clinic. In this report we present methods for estimating the shielding requirements for PET and PET/CT facilities. Information about the physical properties of the most commonly used clinical PET radionuclides is summarized, although the report primarily refers to fluorine-18. Typical PET imaging protocols are reviewed and exposure rates from patients are estimated including self-attenuation by body tissues and physical decay of the radionuclide. Ex- amples of barrier calculations are presented for controlled and noncontrolled areas. Shielding for adjacent rooms with scintillation cameras is also discussed. Tables and graphs of estimated trans- mission factors for lead, steel, and concrete at 0.511 MeV are also included. Meeting the regulatory limits for uncontrolled areas can be an expensive proposition. Careful planning with the equipment vendor, facility architect, and a qualified medical physicist is necessary to produce a cost effective design while maintaining radiation safety standards. Medical Physics, 33, 4-15 (2006) https://doi.org/10.1118/1.2135911 Altmetrics for this report Keywords: Nuclear Medicine, PET-CT Shielding Requirements, Lead Concrete Iron, Uptake Room, Above and Below PET Room Nuclear Medicine Subcommittee Task Group #108 Mark T. Madsen, Jon A. Anderson, James R. Halama, Jeff Kleck, Douglas J. Simpkin, John R. Votaw, Richard E. Wendt III, Lawrence E. Williams, Michael V. Yester Committee Responsible: Nuclear Medicine Subcommittee Last Review Date: |
DISCLAIMER